Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — FLORetina – ICOOR 12th International Congress on OCT and OCT Angiography 2024
12 slides from Eyepoint's conference presentation, Dec 6, 2024
Slide 1: DURAVYU in Diabetic Eye Disease: VERONA Phase 2 Interim Results in Diabetic Macular Edema
DURAVYUTM (vorolanib intravitreal insert) in Diabetic Eye Disease: VERONA Phase 2 Interim Results in Diabetic Macular Edema Ramiro Ribeiro, MD, PhD, Chief Medical Officer EyePoint Pharmaceuticals, Inc, Watertown, MA Presented at FLORetina – ICOOR 12th International Congress on OCT and OCT Angiograph
Slide 2: Disclosures
Presenter Disclosures Employee of EyePoint Pharmaceuticals Inc. Study Disclosures Disclosures These data are preliminary. Conclusive evidence of efficacy and safety of DURAVYU will require further investigation in well- controlled Phase 3 clinical trials. Funding was provided by EyePoint Pharmaceuti
Slide 3: DURAVYU (EYP-1901): Vorolanib Intravitreal Insert
DURAVYUTM (EYP-1901): Vorolanib Intravitreal Insert DURAVYU Vorolanib Durasert ETM Intravitreal Insert Controlled release over a Potent receptor tyrosine kinase Bioerodible, sustained period of at least 6 months inhibitor (TKI): selectively inhibits all IVT drug delivery VEGF signaling No delay – re
Slide 4: Phase 2 VERONA Clinical Trial: Randomized, Open-Label, Aflibercept-Controlled Trial
Phase 2 VERONA Clinical Trial: Randomized, Open-Label, Aflibercept-Controlled Trial Evaluating DURAVYU as a Potential Maintenance Therapy for DME Primary Objectives EYP-1901 dosing endpoint Evaluate the safety and efficacy Screen Day 1 W4 W8 W12 W16 W20 W24 of DURAVYU in DME and −D28 to −D7 collect
Slide 5: VERONA Clinical Trial Criteria for Supplemental Anti-VEGF
VERONA Clinical Trial Criteria for Supplemental Anti-VEGF Starting at Week 4 Starting at Week 12 BCVA reduction 5–9 letters AND CST increase >75 µm Lack of 10% reduction in CST on 2 consecutive visitsa,b vs Baseline (Day 1)b OR Prespecified BCVA reduction ≥10 letters due to DMEa criteria for OR supp
Slide 6: Baseline BCVA and CST Demonstrate Patients Have Active DME
Baseline BCVA and CST Demonstrate Patients Have Active DME DURAVYU 1.3 mg DURAVYU 2.7 mg Aflibercept 2 mg q8W (n = 10) (n = 11) (n = 6) Baseline Characteristics, study eye BCVA, mean ETDRS letter score 66.9 65.5 67.5 (range) (53–75) (46–75) (57–73) CST, mean μm 405.2 421.0 400.3 (range) (342–589) (3
Slide 7: DURAVYU-Treated Eyes Demonstrated Clinically Meaningful Improvement in BCVA at 16 Weeks
Late-breaking interim results in DME | All patients have completed Week 16 visit DURAVYU-Treated Eyes Demonstrated Clinically Meaningful Improvement in BCVA at 16 Weeks BCVA Change from Baseline BCVA mean change from baseline, Mean change vs aflibercept +8.9 ETDRS letters +5.7 letters +3.8 +0.6 lett
Slide 8: DURAVYU-Treated Eyes Demonstrated Improved and Controlled Anatomy, Mirroring BCVA Results
Late-breaking interim results in DME | All patients have completed Week 16 visit DURAVYU-Treated Eyes Demonstrated Improved and Controlled Anatomy, Mirroring BCVA Results CST Change from Baseline CST mean change from baseline, Mean change vs aflibercept −30.5 –8.5 μm −39.0 µm –37.6 μm −68.1 ~38 μm b
Slide 9: Greater Proportion of DURAVYU-Treated Eyes Were Supplement Free vs. Aflibercept Control
Late-breaking interim results | All patients have completed Week 16 visit Greater Proportion of DURAVYU-Treated Eyes Were Supplement Free vs. Aflibercept Control at 16 Weeks Summary of Cumulative Supplement-Free Rates by Weeka 100% 100% 100% 100% Eyes supplemental-injection–free, % 100% 100% Majorit
Slide 10: Patient Case 1 – DURAVYU 2.7 mg
Late-breaking interim results | All patients have completed Week 16 visit Patient Case 1 – DURAVYU 2.7 mg Day 1 Week 4 Week 16 BCVA: 46 BCVA: 65 BCVA: 67 No supplemental anti-VEGF was administered through week 16 BCVA, best-corrected visual acuity; VEGF, vascular endothelial growth factor. VERONA Cl
Slide 11: Patient Case 2 – DURAVYU 2.7 mg
Late-breaking interim results | All patients have completed Week 16 visit Patient Case 2 – DURAVYU 2.7 mg Day 1 Week 4 Week 16 BCVA: 75 BCVA: 83 BCVA: 79 No supplemental anti-VEGF was administered through week 16 BCVA, best-corrected visual acuity; VEGF, vascular endothelial growth factor. VERONA Cl
Slide 12: Positive Interim Data for Ongoing Phase 2 VERONA Clinical Trial
Interim results | All patients have completed Week 16 visit • DURAVYU 2.7 mg demonstrated an early and sustained improvement in both BCVA and CST • Eyes treated with DURAVYU 2.7 mg improved Positive Interim Data for nearly 6 letters more than aflibercept control Ongoing Phase 2 • Eyes treated with D